Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Vania Lo Presti, Angelo Meringa, Ester Dunnebach, Alice van Velzen, Aida Valera Moreira, Ronald W Stam, Rishi S Kotecha, Anja Krippner-Heidenreich, Olaf T Heidenreich, Maud Plantinga, Annelisa Cornel, Zsolt Sebestyen, Jurgen Kuball, Niek P van Til, S Nierkens
BACKGROUND: Hematopoietic cell transplantation (HCT) is an effective treatment for pediatric patients with high-risk, refractory, or relapsed acute myeloid leukemia (AML). However, a large proportion of transplanted patients eventually die due to relapse. To improve overall survival, we propose a combined strategy based on cord blood (CB)-HCT with the application of AML-specific T cell receptor (TCR)-engineered T cell therapy derived from the same CB graft. METHODS: We produced CB-CD8+ T cells expressing a recombinant TCR (rTCR) against Wilms tumor 1 (WT1) while lacking endogenous TCR (eTCR) expression to avoid mispairing and competition...
April 5, 2024: Journal for Immunotherapy of Cancer
#2
JOURNAL ARTICLE
Amogh Agrawal, Suryanarayanan Balakrishnan, Manish J Gandhi, Mariam P Alexander, Lynn Cornell, Andrew J Bentall, Aleksandra Kukla, Mark Stegall, Carrie A Schinstock
BACKGROUND: Microvascular inflammation (MVI) is a key feature of antibody-mediated rejection (AMR) among patients with HLA donor-specific antibody (DSA), but MVI at AMR thresholds (Banff glomerulitis [g] + peritubular capillaritis [ptc] score ≥ 2) without DSA has been increasingly recognized. We aimed to determine the incidence of MVI among highly sensitized kidney transplant recipients without DSA. METHODS: We performed a single-center, retrospective, matched cohort study comparing outcomes of kidney transplant recipients with cPRA ≥90% with preexisting DSA (n = 49), cPRA ≥90% without preexisting DSA (n = 47), and matched controls with cPRA = 0 without preexisting DSA (n = 49)...
April 5, 2024: Transplantation
#3
Lynn D Cornell, Divya Shankaranarayanan, Pablo Serrano Rodriguez, Sibel Erdogan Damgard
No abstract text is available yet for this article.
April 2024: Kidney International
#4
JOURNAL ARTICLE
Daniel Yoo, Gillian Divard, Marc Raynaud, Aaron Cohen, Tom D Mone, John Thomas Rosenthal, Andrew J Bentall, Mark D Stegall, Maarten Naesens, Huanxi Zhang, Changxi Wang, Juliette Gueguen, Nassim Kamar, Antoine Bouquegneau, Ibrahim Batal, Shana M Coley, John S Gill, Federico Oppenheimer, Erika De Sousa-Amorim, Dirk R J Kuypers, Antoine Durrbach, Daniel Seron, Marion Rabant, Jean-Paul Duong Van Huyen, Patricia Campbell, Soroush Shojai, Michael Mengel, Oriol Bestard, Nikolina Basic-Jukic, Ivana Jurić, Peter Boor, Lynn D Cornell, Mariam P Alexander, P Toby Coates, Christophe Legendre, Peter P Reese, Carmen Lefaucheur, Olivier Aubert, Alexandre Loupy
In kidney transplantation, day-zero biopsies are used to assess organ quality and discriminate between donor-inherited lesions and those acquired post-transplantation. However, many centers do not perform such biopsies since they are invasive, costly and may delay the transplant procedure. We aim to generate a non-invasive virtual biopsy system using routinely collected donor parameters. Using 14,032 day-zero kidney biopsies from 17 international centers, we develop a virtual biopsy system. 11 basic donor parameters are used to predict four Banff kidney lesions: arteriosclerosis, arteriolar hyalinosis, interstitial fibrosis and tubular atrophy, and the percentage of renal sclerotic glomeruli...
January 16, 2024: Nature Communications
#5
JOURNAL ARTICLE
Maarten Naesens, Candice Roufosse, Mark Haas, Carmen Lefaucheur, Roslyn B Mannon, Benjamin A Adam, Olivier Aubert, Georg A Böhmig, Jasper Callemeyn, Marian Clahsen-van Groningen, Lynn D Cornell, Anthony J Demetris, Cinthia B Drachenberg, Gunilla Einecke, Agnes B Fogo, Ian W Gibson, Philip Halloran, Luis G Hidalgo, Catherine Horsfield, Edmund Huang, Željko Kikić, Nicolas Kozakowski, Brian Nankivell, Marion Rabant, Parmjeet Randhawa, Leonardo V Riella, Ruth Sapir-Pichhadze, Carrie Schinstock, Kim Solez, Anat R Tambur, Olivier Thaunat, Chris Wiebe, Dina Zielinski, Robert Colvin, Alexandre Loupy, Michael Mengel
The XVI-th Banff Meeting for Allograft Pathology was held at Banff, Alberta, Canada, from 19th to 23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30th anniversary of the first Banff Classification, premeeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis...
March 2024: American Journal of Transplantation
#6
JOURNAL ARTICLE
Candice Roufosse, Maarten Naesens, Mark Haas, Carmen Lefaucheur, Roslyn B Mannon, Marjan Afrouzian, Nada Alachkar, Olivier Aubert, Serena M Bagnasco, Ibrahim Batal, Chris O C Bellamy, Verena Broecker, Klemens Budde, Marian Clahsen-Van Groningen, Shana M Coley, Lynn D Cornell, Darshana Dadhania, Anthony J Demetris, Gunilla Einecke, Alton B Farris, Agnes B Fogo, John Friedewald, Ian W Gibson, Catherine Horsfield, Edmund Huang, Syed A Husain, Annette M Jackson, Jesper Kers, Željko Kikić, Amanda Klein, Nicolas Kozakowski, Helen Liapis, Massima Mangiola, Robert A Montgomery, Brian Nankinvell, Desley A H Neil, Peter Nickerson, Marion Rabant, Parmjeet Randhawa, Leonardo V Riella, Ivy Rosales, Virginie Royal, Ruth Sapir-Pichhadze, Pinaki Sarder, Minnie Sarwal, Carrie Schinstock, Mark Stegall, Kim Solez, Jeroen van der Laak, Chris Wiebe, Robert B Colvin, Alexandre Loupy, Michael Mengel
The XVIth Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from September 19 to 23, 2022, as a joint meeting with the Canadian Society of Transplantation. In addition to a key focus on the impact of microvascular inflammation and biopsy-based transcript analysis on the Banff Classification, further sessions were devoted to other aspects of kidney transplant pathology, in particular T cell-mediated rejection, activity and chronicity indices, digital pathology, xenotransplantation, clinical trials, and surrogate endpoints...
November 4, 2023: American Journal of Transplantation
#7
REVIEW
Joseph Mikhael, Allie Cichewicz, Elizabeth S Mearns, Allicia Girvan, Vicki Pierre, Neda Al Rawashdh, Archibong Yellow-Duke, R Frank Cornell, Michael Nixon
Multiple myeloma (MM) accounts for 10% of hematologic cancers in the U.S.; however, incidence and mortality occur disproportionately between racial groups in real-world settings. Our study's objective was to systematically characterize the disparities in overall survival (OS) among Black and White patients with MM in the US using real-world evidence studies. A systematic literature review was undertaken by searching Embase and MEDLINE for observational studies conducted in the US, published between January 1, 2015 and October 25, 2021, and reporting OS for Black and White patients with MM...
October 10, 2023: Clinical Lymphoma, Myeloma & Leukemia
#8
JOURNAL ARTICLE
Alton B Farris, Mariam P Alexander, Ulysses G J Balis, Laura Barisoni, Peter Boor, Roman D Bülow, Lynn D Cornell, Anthony J Demetris, Evan Farkash, Meyke Hermsen, Julien Hogan, Renate Kain, Jesper Kers, Jun Kong, Richard M Levenson, Alexandre Loupy, Maarten Naesens, Pinaki Sarder, John E Tomaszewski, Jeroen van der Laak, Dominique van Midden, Yukako Yagi, Kim Solez
The Banff Digital Pathology Working Group (DPWG) was established with the goal to establish a digital pathology repository; develop, validate, and share models for image analysis; and foster collaborations using regular videoconferencing. During the calls, a variety of artificial intelligence (AI)-based support systems for transplantation pathology were presented. Potential collaborations in a competition/trial on AI applied to kidney transplant specimens, including the DIAGGRAFT challenge (staining of biopsies at multiple institutions, pathologists' visual assessment, and development and validation of new and pre-existing Banff scoring algorithms), were also discussed...
2023: Transplant International
#9
MULTICENTER STUDY
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt, Kelly N Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D'Souza, Aric C Hall, Pamela Hardwick, James Omel, Robert F Cornell, Parameswaran Hari, Natalie S Callander
BACKGROUND: For patients with newly diagnosed multiple myeloma, reaching minimal residual disease (MRD) negativity after treatment is associated with improved outcomes; however, the use of MRD to modulate therapy remains elusive. We present the final analysis of the MASTER trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy in patients with newly diagnosed multiple myeloma, in which MRD status is used to modulate treatment duration and cessation. METHODS: MASTER was a multicentre, single-arm, phase 2 trial conducted in five academic medical centres in the USA...
November 2023: Lancet Haematology
#10
JOURNAL ARTICLE
Salvatore E Mignano, Samih H Nasr, Mary E Fidler, Loren P Herrera Hernandez, Mariam P Alexander, Sanjeev Sethi, Nidia Messias, Tarek Alhamad, Louai Alrata, Sam T Albadri, Lynn D Cornell
Atypical antiglomerular basement membrane (anti-GBM) nephritis can be defined as linear GBM staining for monotypic or polytypic immunoglobulin (Ig) by immunofluorescence (IF) without a diffuse crescentic pattern. We describe the clinicopathologic features of 6 patients (18 biopsies) in this first series of recurrent atypical anti-GBM nephritis after kidney transplantation. Recurrent glomerulonephritis occurred at a mean of 3.8 months posttransplant (range 1-7 months). Three index biopsies were for clinical indication, and 3 were protocol biopsies...
September 27, 2023: American Journal of Transplantation
#11
JOURNAL ARTICLE
Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria, Eden Biltibo, Saurabh Chhabra, Smith Giri, Kelly N Godby, Sonia Gowda, Eva Medvedova, Robert F Cornell, Natalie S Callander, Luciano J Costa
Quadruplet induction, autologous hematopoietic cell transplant (AHCT), and measurable residual disease (MRD) response-adapted consolidation yield an unprecedented depth of response in newly diagnosed multiple myeloma. Patients treated on MASTER (NCT03224507) ceased therapy and entered active surveillance (MRD-SURE) after achieving MRD negativity. This study characterizes quantitative changes in the immunoglobulin (Ig) gene repertoire by next-generation sequencing and serum gamma globulin levels. Quadruplet therapy leads to profound hypogammaglobulinemia and reduction in the Ig gene repertoire...
August 2023: EJHaem
#12
JOURNAL ARTICLE
Bradley S Podd, Russell K Banks, Ron Reeder, Russell Telford, Richard Holubkov, Joseph Carcillo, Robert A Berg, David Wessel, Murray M Pollack, Kathleen Meert, Mark Hall, Christopher Newth, John C Lin, Allan Doctor, Tom Shanley, Tim Cornell, Rick E Harrison, Athena F Zuppa, Katherine Sward, J Michael Dean, Adrienne G Randolph
OBJECTIVES: Sepsis-associated immune suppression correlates with poor outcomes. Adult trials are evaluating immune support therapies. Limited data exist to support consideration of immunomodulation in pediatric sepsis. We tested the hypothesis that early, persistent lymphopenia predicts worse outcomes in pediatric severe sepsis. DESIGN: Observational cohort comparing children with severe sepsis and early, persistent lymphopenia (absolute lymphocyte count < 1,000 cells/µL on 2 d between study days 0-5) to children without...
December 1, 2023: Critical Care Medicine
#13
JOURNAL ARTICLE
Kevin S Ackerman, Katherine L Hoffman, Iván Díaz, Will Simmons, Karla V Ballman, Rosy P Kodiyanplakkal, Edward J Schenck
BACKGROUND: Patients who have undergone solid organ transplants (SOT) have an increased risk for sepsis compared with the general population. Paradoxically, studies suggest that SOT patients with sepsis may experience better outcomes compared with those without a SOT. However, these analyses used previous definitions of sepsis. It remains unknown whether the more recent definitions of sepsis and modern analytic approaches demonstrate a similar relationship. METHODS: Using the Weill Cornell-Critical Care Database for Advanced Research, we analyzed granular physiologic, microbiologic, comorbidity, and therapeutic data in patients with and without SOT admitted to intensive care units (ICUs)...
April 2023: Open Forum Infectious Diseases
#14
JOURNAL ARTICLE
Mădălin Guliciuc, Daniel Porav-Hodade, Bogdan-Calin Chibelean, Septimiu Toader Voidazan, Veronica Maria Ghirca, Adrian Cornel Maier, Monica Marinescu, Dorel Firescu
Background and Objectives : Patients with urinary tract obstruction (UTO) and systemic inflammatory response syndrome (SIRS) are at risk of developing urosepsis, whose evolution involves increased morbidity, mortality and cost. The aim of this study is to evaluate the ability of already existing scores and biomarkers to diagnose, describe the clinical status, and predict the evolution of patients with complicated urinary tract infection (UTI) and their risk of progressing to urosepsis. Materials and Methods : We conducted a retrospective study including patients diagnosed with UTI hospitalized in the urology department of" Sfântul Apostol Andrei" County Emergency Clinical Hospital (GCH) in Galati, Romania, from September 2019 to May 2022...
March 17, 2023: Medicina
#15
REVIEW
Taryn B Bainum, Kelly R Reveles, Ronald G Hall, Kelli Cornell, Carlos A Alvarez
Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and mortality, especially for high-risk groups that include immunocompromised patients. Both the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America (IDSA/SHEA), as well as the American College of Gastroenterology (ACG) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recently provided guideline updates for C. difficile infection (CDI). In this narrative review, the authors reviewed available literature regarding the prevention or treatment of CDI in adults and focused on disagreements between the IDSA/SHEA and ACG guidelines, as well as articles that have been published since the updates...
February 3, 2023: Microorganisms
#16
Simon Moubarak, Loren P Herrera Hernandez, Lynn D Cornell, Tiffany Caza, Ladan Zand
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is the second most common monoclonal gammopathy of renal significance. Rates of progression to kidney failure as well as rates of recurrence after kidney transplantation are high, especially in the absence of treatment. Treatment is usually targeted toward the abnormal clone, but even in the absence of an identifiable clone, empiric treatment is still recommended to avoid worsening prognosis. In this report, we present an unusual course of a PGNMID case with a relapsing and remitting pattern of illness, likely triggered by infection and vaccination...
January 2023: Kidney medicine
#17
JOURNAL ARTICLE
Saurabh Chhabra, Natalie Callander, Nicole L Watts, Luciano J Costa, Bicky Thapa, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Larry D Anderson, Susan Bal, Binod Dhakal, Nitya Nathwani, Nina Shah, Eva Medvedova, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Timothy Schmidt, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Bhagirathbhai Dholaria, R Frank Cornell, James H Jerkins, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Saad Z Usmani, Paul G Richardson, Peter M Voorhees
For eligible patients with newly diagnosed multiple myeloma (NDMM), standard of care includes induction therapy followed by autologous stem cell transplantation (ASCT). Daratumumab as monotherapy and in combination treatment is approved across multiple lines of therapy for multiple myeloma (MM), and lenalidomide is an effective and commonly used agent for induction and maintenance therapy in MM. However, there is concern that lenalidomide and daratumumab given as induction therapy might impair mobilization of stem cells for ASCT...
March 2023: Transplantation and cellular therapy
#18
JOURNAL ARTICLE
Thalia Salinas, Carol Li, Catherine Snopkowski, Gabriel Stryjniak, Divya Shankaranarayanan, Shady Albakry, Ruchuang Ding, Vijay K Sharma, Steven P Salvatore, Surya V Seshan, Darshana M Dadhania, Thangamani Muthukumar, Manikkam Suthanthiran
BACKGROUND: We developed urinary cell mRNA profiling for noninvasive diagnosis of acute T cell mediated rejection (TCMR) and BK virus nephropathy (BKVN), two significant post-transplant complications. Our profiling protocol for the multicenter Clinical Trial of Transplantation-04 (CTOT-04) study consisted of centrifugation of urine to prepare cell pellets, washes, addition of an RNA preservative, storage at 800 C and shipment in cold containers to our Gene Expression Monitoring (GEM) Core for RNA isolation and quantification of mRNA in RT-qPCR assays...
January 2023: Journal of Immunological Methods
#19
JOURNAL ARTICLE
Mireille El Ters, Filippo Pinto E Vairo, Carri Prochnow, Carrie Schinstock, Patrick Dean, Jennifer Kemppainen, Konstantinos Lazaridis, Fernando Cosio, Fernando C Fervenza, Lynn Cornell, Hatem Amer, Marie C Hogan
BACKGROUND: Recent studies identified underlying genetic causes in a proportion of patients with various forms of kidney disease. In particular, genetic testing reclassified some focal segmental glomerulosclerosis (FSGS) cases into collagen type 4 (COL4)-related nephropathy. This knowledge has major implications for counseling prospective transplant recipients about recurrence risk and screening biologically related donors. We describe our experience incorporating genetic testing in our kidney transplant multidisciplinary practice...
October 18, 2022: Transplantation
#20
JOURNAL ARTICLE
Susan Bal, Binod Dhakal, Rebecca W Silbermann, Timothy M Schmidt, Bhagirathbhai Dholaria, Smith Giri, Saurabh Chhabra, Eva Medvedova, Kelly N Godby, Anita D'Souza, Aric C Hall, Pamela Hardwick, Jim Omel, Robert F Cornell, Parameswaran Hari, Natalie S Callander, Luciano J Costa
The incremental impact of autologous hematopoietic cell transplantation (AHCT) on disease burden with quadruplet induction in newly diagnosed multiple myeloma (NDDM) can be reappraised with the serial assessment of minimal residual disease (MRD). We describe the impact of AHCT on MM burden assessed by next-generation sequencing (NGS) for patients enrolled in a clinical trial utilizing quadruplet induction, AHCT, followed by MRD-adapted consolidation. We describe quantitative changes in MRD burden with AHCT and explore patient and disease features influencing the magnitude of MRD reduction with AHCT...
June 22, 2022: American Journal of Hematology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
